BioWorld MedTech

Feb. 29, 2016

Elite French investors pump fresh $55 million into artificial heart

PARIS — To fund its ramp-up to market, artificial heart maker Paris-based Carmat SA raised €50 million ($55 million) through a reserved capital increase put together by a cluster of elite French institutional investors. Read More

Spectranetics hopeful for a stellar year, fueled by Stellarex DCB

OA trials numerous but endpoints tricky as stakeholders search for another way

International Stroke Conference tPA costs and their impact on AIS therapies addressed at meeting

Panel says a heavy hand will impede use of NGS in oncology

Other News to Note

Appointments & Advancements

Keeping you up to date on recent developments in Neurology

Today's news in brief

BioWorld

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

Illustration of Alzheimer's disease in the brain

ADPD 2026: Three inflection points to target Alzheimer’s disease

BioWorld Science

A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 17, 2026

SERCA inhibitor from Sumitomo shows promise for MSA-C treatment

BioWorld Science

At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, Sumitomo Pharma Co....